Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10

Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, 2150 CCGC, Ann Arbor, MI 48109-0930, USA.
BMC Complementary and Alternative Medicine (Impact Factor: 2.02). 02/2006; 6(1):10. DOI: 10.1186/1472-6882-6-10
Source: PubMed


Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed.
A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complextrade mark, Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 mg.
Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg.
The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.

Download full-text


Available from: Mack T Ruffin IV,
1 Follower
44 Reads
  • Source
    • "Although curcumin has been reported to be well tolerated, there are some reports about adverse effects in humans, mainly in the gastrointestinal tract: diarrhea, nausea, and abdominal pain (Epelbaum et al., 2010; Lao et al., 2006; Sharma et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is a serious world health problem and one of the most studied diseases; a major concern about its treatment is that β-cell mass and functionality is hard to restore. In addition, it is frequently associated with severe complications, such as diabetic nephropathy and cardiomyopathy. The anti-inflammatory, anti-oxidative and anti-apoptotic properties of curcumin have made it a promising molecule for the treatment of this pathology; however, its solubility and bioavailability problems are still the subject of multiple studies. To cope with those difficulties, several approaches have been evaluated, such as the development of pharmaceutical formulations and curcumin analogues. This review discusses some of the studied therapeutic targets for curcumin in diabetes as well as the structural characteristics and targets of its analogues. The shortening of the central seven-carbon chain of curcumin has given rise to compounds without glucose-lowering effects but potentially useful for the treatment of diabetes complications; whereas preserving this chain retains the glucose-lowering properties. Most of the analogues discussed here have been recently synthesized and tested in animal models of type 1 diabetes; more studies in models of type 2 diabetes are needed. Copyright © 2015. Published by Elsevier B.V.
    European Journal of Pharmacology 03/2015; 756. DOI:10.1016/j.ejphar.2015.02.045 · 2.53 Impact Factor
  • Source
    • "Over 2400 metric tons of turmeric are imported into the USA (Sharma et al., 2005). The average intake of turmeric in the Indian diet is approximately 2–2.5 g for a 60 kg individual, which corresponds to a daily intake of approximately 60–100 mg of curcumin (Shah et al., 1999; Lao et al., 2006; Tayyem et al., 2006). In addition, curcumin has entered scientific clinical trials at the phase I, II and III levels for its therapeutic efficacy, even at doses as high as 12 g/ day during 3 months (Cheng et al., 2001; Hsu and Cheng, 2007; NIH, 2007; Dhillon et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Occupational or environmental exposures to heavy metals produce several adverse health effects. The common mechanism determining their toxicity and carcinogenicity is the generation of oxidative stress that leads to hepatic damage. In addition, oxidative stress induced by metal exposure leads to the activation of the nuclear factor (erythroid-derived 2)-like 2/Kelch-like ECH-associated protein 1/antioxidant response elements (Nrf2/Keap1/ARE) pathway. Since antioxidant and chelating agents are generally used for the treatment of heavy metals poisoning, this review is focused on the protective role of curcumin against heavy metals liver injury. Curcumin has shown, in clinical and preclinical studies, numerous biological activities including therapeutic efficacy against various human diseases and anti-hepatotoxic effects against environmental or occupational toxins. Curcumin reduces the hepatotoxicity induced by arsenic, cadmium, chromium, copper, lead and mercury, prevents histological injury, lipid peroxidation and glutathione (GSH) depletion, maintains the liver antioxidant enzyme status and protects against mitochondrial dysfunction. The preventive effect of curcumin on the noxious effects induced by heavy metals has been attributed to its scavenging and chelating properties, and/or to the ability to induce the Nrf2/Keap1/ARE pathway. However, additional research is needed in order to propose curcumin as a potential protective agent against liver damage induced by heavy metals.
    Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 04/2014; 69. DOI:10.1016/j.fct.2014.04.016 · 2.90 Impact Factor
  • Source
    • "Curcumin has been known as an extremely safe compound at high dose. Lao et al., reported although healthy volunteers were administered doses from 500 to 12,000 mg, only 30% of volunteers had minimal toxicity that was not related with dose of curcumin [64]. For chemoprevention in human, curcumin is required daily 1.6 g/person [65]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The PI3K/Akt and mTOR signaling pathways are important for cell survival and growth, and they are highly activated in cancer cells compared with normal cells. Therefore, these signaling pathways are targets for inducing cancer cell death. The dual PI3K/Akt and mTOR inhibitor NVP-BEZ235 completely inhibited both signaling pathways. However, NVP-BEZ235 had no effect on cell death in human renal carcinoma Caki cells. We tested whether combined treatment with natural compounds and NVP-BEZ235 could induce cell death. Among several chemopreventive agents, curcumin, a natural biologically active compound that is extracted from the rhizomes of Curcuma species, markedly induced apoptosis in NVP-BEZ235-treated cells. Co-treatment with curcumin and NVP-BEZ235 led to the down-regulation of Mcl-1 protein expression but not mRNA expression. Ectopic expression of Mcl-1 completely inhibited curcumin plus NVP-NEZ235-induced apoptosis. Furthermore, the down-regulation of Bcl-2 was involved in curcumin plus NVP-BEZ235-induced apoptosis. Curcumin or NVP-BEZ235 alone did not change Bcl-2 mRNA or protein expression, but co-treatment reduced Bcl-2 mRNA and protein expression. Combined treatment with NVP-BEZ235 and curcumin reduced Bcl-2 expression in wild-type p53 HCT116 human colon carcinoma cells but not p53-null HCT116 cells. Moreover, Bcl-2 expression was completely reversed by treatment with pifithrin-α, a p53-specific inhibitor. Ectopic expression of Bcl-2 also inhibited apoptosis in NVP-BE235 plus curcumin-treated cells. In contrast, NVP-BEZ235 combined with curcumin did not have a synergistic effect on normal human skin fibroblasts and normal human mesangial cells. Taken together, combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
    PLoS ONE 04/2014; 9(4):e95588. DOI:10.1371/journal.pone.0095588 · 3.23 Impact Factor
Show more